Quidel Corp
Gesloten
10.31 -9.48
Overzicht
Wijziging aandelenprijs
24u
Min
10.29
Max
11.07
Inkomsten | 39M -92M |
|---|---|
Verkoop | -104M 620M |
Winstmarge | -14.811 |
Werknemers | 6,500 |
Aanbevelingen | Neutraal |
|---|---|
12 Maanden Prognose | +16.57% upside |
Volgende Winsten | 4 aug 2026 |
|---|
Marktkapitalisatie | -140M 560M |
|---|---|
Vorige openingsprijs | 19.79 |
Vorige sluitingsprijs | 10.31 |
Quidel Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Quidel Corp Prognose
Koersdoel
By TipRanks
16.57% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 12.03 USD 16.57%
Hoogste 13 USD
Laagste 11 USD
Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Quidel Corp - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
Operationele winst
$
Over Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
